Completion of therapeutic and safety monitoring tests in lebanese outpatients on chronic medications: A cross-sectional study

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1195-1204

  Ramia, Elsy ^a   Zeenny, Rony ^a  

^a LEBANESE AMERICAN UNIVERSITY   (Lebanon)

Author keywords

Chronic diseases; Diabetes; Disease management; Drugs; Hypertension; Laboratory tests; Primary care; Statins

Indexed keywords

ACENOCOUMAROL; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; LITHIUM; ORAL ANTIDIABETIC AGENT; VALPROIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH SURVEY; HUMAN; LABORATORY TEST; LEBANESE; LEBANON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT CARE; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE;

EID: 84937578227     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S69250     Document Type: Article

References (53)

1. Hurley JS, Roberts M, Solberg LI, et al. Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med. 2005;20(4):331–333.
2. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambu­latory care. N Engl J Med. 2003;348(16):1556–1564.
3. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107–1116.
4. Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005; 118(3):251–258.
5. Raebel MA, Lyons EE, Andrade SE, et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med. 2005;20(12):1120–1126.
6. Institute of Medicine. To Err Is Human: Building a Safer Health System. Washington, DC: National Academies Press; 2000.
7. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva, Switzerland: World Health Organization; 2002. Available from: http://apps.who.int/medi­cinedocs/en/d/Js4893e.html. Accessed June 24, 2014.
8. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). Anti-Vitamine K (AVK). Saint-Denis, France: ANSM; 2014. Available from: http://ansm.sante.fr/Dossiers/Anti-vitamine-K-AVK/Information-pour-les-professionnels-de-sante/(offset)/2. Accessed June 24, 2014.
9. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Associa­tion; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–1711.
10. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68(11):2189–2196.
11. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000;160(12):1741–1748.
12. American Diabetes Association. Executive summary: standards of medi­cal care in diabetes – 2011. Diabetes Care. 2011;34 Suppl 1:S4–S10.
13. Glucophage®, Glucophage® XR (extended-release oral tablets, oral tablets) [package insert]. Princeton NJ: Bristol-Myers Squibb; 2009.
14. Pickering T. Recommendations for the use of home (self) and ambula­tory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel. Am J Hypertens. 1996;9(1):1–11.
15. Bloomberg MR, Frieden TR. Patient Self-Monitoring of Blood Pressure: A Provider’s Guide. New York, NY: The New York City Department of Health and Mental Hygiene; 2014. Available from: http://www.nyc.gov/html/doh/downloads/pdf/csi/hyperkit-hcp-bpselfmon-guide.pdf. Accessed June 24, 2014.
16. Watts NB, Bilezikian JP, Camacho PM, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists Medi­cal Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010;16 Suppl 3:1–37.
17. National Institute for Health and Clinical Excellence. Bipolar Disorder: the Management of Bipolar Disorder in Adults, Children and Ado­lescents, in Primary and Secondary Care. Manchester, UK: National Institute for Health and Clinical Excellence; 2006. Available from: http://www.nice.org.uk/guidance/cg38/resources/guidance-bipolar-disorder-pdf. Accessed June 24, 2014.
18. Tegretol® (oral chewable tablets, tablets, suspension) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
19. Epocrates. Cyclosporine modified: black box warnings [webpage on the Internet]. San Mateo, CA: Epocrates; 2014. Available from: https://online.epocrates.com/u/10b4183/cyclosporine+modified/Black+Box+Warnings. Accessed June 24, 2014.
20. Sandimmune® (oral capsules, oral solution, intravenous injection) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corpora­tion; 2010.
21. National Institute for Health and Clinical Excellence. Chronic Heart Failure: Management of Chronic Heart Failure in Adults in Primary and Secondary Care. Manchester, UK: National Institute for Health and Clinical Excellence; 2010. Available from: http://www.nice.org.uk/guidance/cg108/resources/guidance-chronic-heart-failure-pdf. Accessed June 24, 2014.
22. Goldsmith LA, Bolognia JL, Callen JP, et al; American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004;50(6):900–906.
23. Rodgers P, Bassler M. Treating onychomycosis. Am Fam Physician. 2001;63(4):663–672.677–678.
24. Dilantin® (extended phenytoin sodium capsules, USP) [package insert]. New York, NY: Pfizer Inc; 2009.
25. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Asso­ciation; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–572.
26. Demers LM, Spencer CA. The National Academy of Clinical Biochemis­try Laboratory Medicine Practice Guidelines. Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. Washington, DC: National Academy of Clinical Biochemistry; 2002. Available from: http://www.aacc.org/SiteCollectionDocuments/Archived%20and%20Historical/ThyroidArchived2010.pdf#page=1. Accessed June 24, 2014.
27. Central Intelligence Agency. The world factbook webpage on the Inter­net. Washington, DC: US Central Intelligence Agency; 2014 [updated June 20, 2014]. Available from: https://www.cia.gov/library/publica­tions/the-world-factbook/geos/le.html. Accessed June 24, 2014.
28. Krecke HJ, Lütkes P, Maiwald M. Patient assessment of self-measurement of blood pressure: results of a telephone survey in Germany. J Hypertens. 1996;14(3):323–326.
29. Cuspidi C, Meani S, Lonati L, et al; Lombardy Regional Section of the Italian Hypertension Society. Prevalence of home blood pressure mea­surement among selected hypertensive patients: results of a multicenter survey from six hospital outpatient hypertension clinics in Italy. Blood Press. 2005;14(4):251–256.
30. Baral-Grant S, Haque MS, Nouwen A, Greenfield SM, McManus RJ. Self-monitoring of blood pressure in hypertension: a UK primary care survey. Int J Hypertens. 2012;2012:582068.
31. Parcero AF, Yaeger T, Bienkowski RS. Frequency of monitoring hemo­globin A1C and achieving diabetes control. J Prim Care Community Health. 2011;2(3):205–208.
32. Tragni E, Filippi A, Mazzaglia G, Sessa E, Cricelli C, Catapano AL. Monitoring statin safety in primary care. Pharmacoepidemiol Drug Saf. 2007;16(6):652–657.
33. Kjeldsen SE, Aksnes TA, Ruilope LM. Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D. 2014;14(2):31–43.
34. Pickering T., Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697–716.
35. Calhoun DA, Jones D, Textor S, et al; American Heart Association Pro­fessional Education Committee. Resistant hypertension: diagnosis, eval­uation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–e526.
36. Parati G, Stergiou G., Asmar R, et al; ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitor­ing. J Hypertens. 2008;26(8):1505–1526.
37. Parati G, Stergiou G, O’Brien E, et al; European Society of Hyperten­sion Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7): 1359–1366.
38. O’Brien E, Parati G, Stergiou G. Ambulatory blood pressure measure­ment: what is the international consensus? Hypertension. 2013;62(6): 988–994.
39. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
40. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1):3–16.
41. Doyle-Campbell C. European Society of Hypertension and European Society of Cardiology guidelines and the muted enthusiasm for home blood pressure monitoring. Hypertension. 2014;63(2):e5.
42. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15.
43. Jaques H; National Institute for Health and Clinical Excellence (NICE). NICE guideline on hypertension. Eur Heart J. 2013;34(6):406–408.
44. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216–2224.
45. US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs [webpage on the Internet]. Silver Spring, MD: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed June 24, 2014.
46. Kjeldsen LJ, Bjerrum L, Herborg H, Knudsen P, Rossing C, Søndergaard B. Development of new concepts of non-adherence measurements among users of antihypertensives medicines. Int J Clin Pharm. 2011;33(3):565–572.
47. Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualita­tive study. Patient Prefer Adherence. 2014;8:237–246.
48. Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2000;(2):CD000011.
49. Goldman RE, Soran CS, Hayward GL, Simon SR. Doctors’ perceptions of laboratory monitoring in office practice. J Eval Clin Pract. 2010; 16(6):1136–1141.
50. Millar A, Cauch-Dudek K, Shah BR. The impact of diabetes education on blood glucose self-monitoring among older adults. J Eval Clin Pract. 2010;16(4):790–793.
51. Shah SG, Barnett J, Kuljis J, Hone K, Kaczmarski R. Factors determin­ing patients’ intentions to use point-of-care testing medical devices for self-monitoring: the case of international normalized ratio self-testing. Patient Prefer Adherence. 2013;7:1–14.
52. Feldstein AC, Smith DH, Perrin N, et al. Improved therapeutic monitor­ing with several interventions: a randomized trial. Arch Intern Med. 2006;166(17):1848–1854.
53. Hoch I, Heymann AD, Kurman I, Valinsky LJ, Chodick G, Shalev V. Countrywide computer alerts to community physicians improve potas­sium testing in patients receiving diuretics. J Am Med Inform Assoc. 2003;10(6):541–546.